PPG introduces PPG LINQ Color software and PPG MAGICBOX body shop assistant for the refinish industry
30.8.2023 16:00:00 EEST | Business Wire | Press release
PPG (NYSE: PPG) today announced the introduction of PPG LINQ™ Color software and the PPG MAGICBOX™ body shop assistant for smarter wireless mixing in automotive repair shops. The advanced tools are the latest components of the PPG LINQ end-to-end digital solution for the global refinish industry that provide productivity and sustainability improvement for body shops.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830721690/en/
The PPG MAGICBOX™ smart device eliminates the need for specialized computers in the mixing room by delivering a PPG patented body shop assistant, connectable to new and existing USB scales in body shops. (Photo: Business Wire)
With PPG LINQ, refinish customers can streamline their repair process by using PPG’s cloud-based platform and its interconnected digital hardware, software and related services. The PPG MagicBox body shop assistant is a small but powerful device that communicates environmental conditions in mixing rooms and receives formulas direct from the PPG LINQ Color software. These new tools also extend the digital ecosystem to smaller body shops not previously served by the PPG LINQ solution.
The PPG LINQ system delivers benefits including faster color-matching from any internet-connected device; less rework and no need for spray-out cards; faster and more efficient paint mixing; and waste reduction, when compared to a traditional repair process.
“When our PPG LINQ digital ecosystem is paired with our industry-leading paint products, we can help body shop owners to realize a 15% ‘key-to-key’ productivity improvement,” said Chancey Hagerty, PPG senior vice president, Automotive Refinish. “From the time a customer leaves their key with a body shop until they return to collect their car, that body shop can achieve improved productivity, reduced waste and enhanced sustainability compared to a traditional repair approach.”
The launch of PPG LINQ Color software and the PPG MagicBox body shop assistant follows the launch of other PPG LINQ digital ecosystem products, including PPG VISUALIZID™ software, the PPG DIGIMATCH™ spectrophotometer and the PPG MOONWALK® system, the company’s award-winning, automated paint mixing system launched in 2019.
“Today, thousands of body shops around the globe already use the PPG MoonWalk, PPG VisualizID and PPG DigiMatch tools,” said Alban d’Epenoux, PPG global marketing director, Automotive Refinish. “The addition of PPG LINQ Color software and the PPG MagicBox device can also mean additional productivity and enhanced capabilities for those existing users and also for thousands of other body shops interested in adopting the best digital solutions to enhance their business performance.”
To learn more about the PPG LINQ digital solution, visit https://ppglinq.com.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
PPG LINQ, MagicBox, Digimatch, and VisualizID are trademarks, and MoonWalk, the PPG Logo and We Protect and Beautify the World are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Automotive Refinish
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830721690/en/
Contact information
Michelle Deemer
Automotive Refinish
+1 412 728 0195
mdeemer@ppg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
